A Phase 4 interventional study of Boostrix™ and Boostrix™-US formulation in Acellular Pertussis, Tetanus and Diphtheria, sponsored by GlaxoSmithKline. Completed at 3 sites in Belgium. Open to participants aged 18 Years to 28 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-20.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing boostrix in Tetanus — 2 open to participants now, 2 under way, none of them phase 3. Boostrix · Tetanus.
Among the 22 studies testing boostrix in Tetanus, this one is the 18th largest by enrollment, is the only one that started in 2010, is one of 8 in phase 4, and was the 11th registered.
318 studies on the registry are indexed under Tetanus; 29 are open to participants now.
Browse Tetanus studies →2 of the 22 studies testing boostrix in Tetanus are open now, in 1 country. Recruiting first, the newest first:
Changchun BCHT Biotechnology Co. · Sites in China
Ages 10+ · Healthy volunteers
Changchun BCHT Biotechnology Co.
Ages 10+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 16 Tetanus studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 28 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2010.
This study's enrollment of 180 is below the median of 418 across 280 interventional studies indexed under Tetanus.
Median enrollment 554 across the 22 interventional studies. Of the 20 that completed or were terminated, 14 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 22 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
106 studies in Tetanus by GlaxoSmithKline: none open now, 1 under way, 1 of them phase 3. Of 104 finished, 62 (60%) have results posted.
Among the 106 studies in Tetanus by GlaxoSmithKline, this one is the 80th largest by enrollment of the 98 interventional ones that give a count, is one of 7 that started in 2010, is one of 22 in phase 4, and was the 64th registered.
GlaxoSmithKline’s Tetanus studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing boostrix in Tetanus, from their registry updates:
Among GlaxoSmithKline’s 106 in Tetanus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the immunogenicity, safety and reactogenicity of a dTpa (Boostrix™ vaccine) booster dose given 10 years after the previous vaccination with dTpa in GSK 263855/029 study. Only subjects who were part of the primary study will be invited to participate in this study.This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate study (see reference).
All subjects will receive a booster dose of the vaccine that they received in their primary study. Subjects who received the investigational vaccine formulation, will receive Boostrix™ in the present study.
Inclusion Criteria:
Female subjects of childbearing potential may receive the booster vaccine, if the subject:
Exclusion Criteria:
Exclusion criteria to be checked at study entry:
Occurrence of any of the following adverse event after a previous administration of a DTP vaccine :
Additional exclusion criteria to be checked for subjects before the booster vaccination administration:
Acute disease and/or fever at the time of enrolment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, reference formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
Biological: Boostrix™
Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, United States(US)-marketed formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, US-marketed formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
Biological: Boostrix™-US formulation
Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, investigational formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
Biological: Boostrix™
Intramuscular, single dose
Intramuscular, single dose
Number of Seroprotected Subjects Against Diphtheria and Tetanus
A subject seroprotected against diphtheria/tetanus was defined as a vaccinated subject who had an anti-diphtheria (anti-D)/anti-tetanus (anti-T) antibody concentration greater than or above (≥) 0.1 international units per milliliter (IU/mL).
Time frame: At Year 8.5
Concentrations for Anti-D and Anti-T Antibodies.
Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL for all antibodies assessed.
Time frame: At Year 8.5
Number of Seroprotected Subjects Against Diphtheria and Tetanus.
A subject seroprotected against diphtheria/tetanus was defined as a vaccinated subject who had an anti-D/anti-T antibody concentration greater than or above (≥) 0.1 international units per milliliter (IU/mL).
Time frame: At Year 10
Concentrations for Anti-D and Anti-T Antibodies.
Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL.
Time frame: At Year 10
Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Haemagglutinin (Anti-FHA) Antibodies.
A seropositive subject for anti-PT/anti-PRN/anti-FHA antibodies was defined as a vaccinated subject who had anti-PT/anti-PRN/anti-FHA antibody concentrations greater than or equal to (≥) 5 Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
Time frame: At Year 8.5
Concentrations for Anti-PT, Anti-PRN and Anti-FHA Antibodies.
Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL for all antibodies assessed.
Time frame: At Year 8.5
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN Antibodies.
A seropositive subject for anti-PT/anti-FHA/anti-PRN antibodies was defined as a vaccinated subject who had anti-PT/anti-FHA/anti-PRN antibody concentrations greater than or equal to (≥) 5 Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
Time frame: At Year 10
Concentrations for Anti-PT, Anti-FHA and Anti-PRN Antibodies.
Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL.
Time frame: At Year 10
Number of Seroprotected Subjects Against Diphtheria and Tetanus
A subject seroprotected against diphtheria/tetanus was defined as a vaccinated subject who had an anti-D/anti-T antibody concentration greater than or above (≥) 0.1 international units per milliliter (IU/mL).
Time frame: At Year 10 pre booster vaccination (PRE) and at 1 month post Year 10 booster vaccination (POST)
Concentrations for Anti-D and Anti-T Antibodies.
Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL for all antibodies assessed.
Time frame: At Year 10 pre booster vaccination (PRE) and at 1 month post Year 10 booster vaccination (POST)
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN Antibodies.
A seropositive subject for anti-PT/anti-PRN/anti-FHA antibodies was defined as a vaccinated subject who had anti-PT/anti-PRN/anti-FHA antibody concentrations greater than or equal to (≥) 5 ELISA units per milliliter (EL.U/mL).
Time frame: At Year 10 pre booster vaccination (PRE) and at 1 month post Year 10 booster vaccination (POST)
Concentrations for Anti-PT, Anti-FHA and Anti-PRN Antibodies.
Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL.
Time frame: At Year 10 pre booster vaccination (PRE) and at 1 month post Year 10 booster vaccination (POST)
Number of Booster Responders to Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antigens.
A booster responder to PT/PRN antigens was defined as either a vaccinated subject seronegative at analysis baseline (Year 10) with anti-PT/anti-PRN antibody concentration greater than or equal to (≥) 5 EL.U/mL at one month post Year 10 booster vaccination, or as a vaccinated subject seropositive at analysis baseline (Year 10) and with anti-PT/anti-PRN antibody concentration with at least a 2-fold increase at one month post Year 10 booster vaccination. A seronegative/seropositive subject was defined as a vaccinated subject with anti-PT/anti-PRN antibody concentration ≥/\< 5 EL.U/mL.
Time frame: At 1 month post Year 10 booster vaccination
Number of Subjects With Any Solicited Local Symptoms.
Assessed solicited local symptoms were pain, redness and swelling at the injection site. Any = incidence of a particular symptom regardless of intensity grade.
Time frame: During the 4-day (Days 0-3) follow-up period after booster vaccination
Number of Subjects With Any Solicited General Symptoms.
Assessed solicited general symptoms were fatigue, gastrointestinal, headache and fever \[defined as axillary temperature ≥ 37.5 degrees Celsius (°C)\]. Any = incidence of a particular symptom regardless of intensity grade and relationship to vaccination.
Time frame: During the 4-day (Days 0-3) follow-up period after booster vaccination
Number of Subjects With Any Unsolicited Adverse Events (AEs).
An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any unsolicited AE = any unsolicited AE regardless of intensity or relationship to vaccination.
Time frame: During the 31-day (Days 0-30) follow-up period after booster vaccination
Number of Subjects With Any Serious Adverse Events (SAEs).
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject..
Time frame: At Year 8.5
Number of Subjects With Any Serious Adverse Events (SAEs).
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: From Year 8.5 up to study end (one month post Year 10 booster vaccination)
Subjects consisted of those previously vaccinated \& boosted in GSK263855/029 study and contacted for participation in this booster (BST) study. Duration of this study was about 19 months, from Year 8.5 (8.5 years post BST in GSK263855/029 study) to one month post BST in this study (Year 10 \[10 years post BST in GSK263855/029 study\] + one month).
| Milestone | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Started | 54 | 60 | 66 |
| Completed | 54 | 60 | 66 |
| Not completed | 0 | 0 | 0 |
| Milestone | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Started | 55 | 60 | 62 |
| Completed | 55 | 59 | 62 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
A subject seroprotected against diphtheria/tetanus was defined as a vaccinated subject who had an anti-diphtheria (anti-D)/anti-tetanus (anti-T) antibody concentration greater than or above (≥) 0.1 international units per milliliter (IU/mL).
| Participants | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Anti-D | 53 | 59 | 65 |
| Anti-T | 54 | 59 | 65 |
Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL for all antibodies assessed.
| IU/mL | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Anti-D | 0.912 (0.728 to 1.141) | 1.205 (0.984 to 1.474) | 0.872 (0.711 to 1.068) |
| Anti-T | 1.889 (1.585 to 2.251) | 1.991 (1.674 to 2.368) | 1.846 (1.604 to 2.123) |
A subject seroprotected against diphtheria/tetanus was defined as a vaccinated subject who had an anti-D/anti-T antibody concentration greater than or above (≥) 0.1 international units per milliliter (IU/mL).
| Participants | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Anti-D | 53 | 60 | 61 |
| Anti-T | 54 | 60 | 61 |
Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL.
| IU/mL | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Anti-D | 0.767 (0.600 to 0.982) | 1.099 (0.882 to 1.370) | 0.681 (0.550 to 0.844) |
| Anti-T | 2.008 (1.650 to 2.444) | 2.009 (1.701 to 2.372) | 1.760 (1.518 to 2.041) |
A seropositive subject for anti-PT/anti-PRN/anti-FHA antibodies was defined as a vaccinated subject who had anti-PT/anti-PRN/anti-FHA antibody concentrations greater than or equal to (≥) 5 Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
| Participants | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Anti-PT [N=54;59;65] | 42 | 48 | 60 |
| Anti-FHA [N=54;59;62] | 54 | 59 | 62 |
| Anti-PRN [N=54;59;65] | 54 | 59 | 65 |
Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL for all antibodies assessed.
| EL.U/mL | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Anti-PT [N=54;59;65] | 10.933 (7.979 to 14.980) | 13.372 (10.139 to 17.634) | 18.034 (13.812 to 23.545) |
| Anti-FHA [N=54;59;62] | 72.653 (57.904 to 91.158) | 96.144 (75.613 to 122.250) | 102.604 (85.687 to 122.861) |
| Anti-PRN [N=54;59;65] | 161.349 (121.750 to 213.827) | 179.027 (136.303 to 235.144) | 134.616 (106.266 to 170.528) |
A seropositive subject for anti-PT/anti-FHA/anti-PRN antibodies was defined as a vaccinated subject who had anti-PT/anti-FHA/anti-PRN antibody concentrations greater than or equal to (≥) 5 Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
| Participants | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Anti-PT [N=52;59;59] | 44 | 49 | 51 |
| Anti-PRN [N=54;60;60] | 54 | 60 | 60 |
| Anti-FHA [N=54;60;60] | 54 | 60 | 60 |
Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL.
| EL.U/mL | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Anti-PT [N=52;59;59] | 11.627 (8.863 to 15.252) | 13.987 (10.874 to 17.991) | 15.728 (11.760 to 21.034) |
| Anti-PRN [N=54;60;60] | 131.814 (98.531 to 176.340) | 158.239 (120.864 to 207.171) | 115.209 (91.288 to 145.398) |
| Anti-FHA [N=54;60;60] | 75.574 (61.018 to 93.603) | 98.182 (77.166 to 124.921) | 98.441 (82.710 to 117.165) |
A subject seroprotected against diphtheria/tetanus was defined as a vaccinated subject who had an anti-D/anti-T antibody concentration greater than or above (≥) 0.1 international units per milliliter (IU/mL).
| Participants | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Anti-D, PRE | 53 | 59 | 60 |
| Anti-D, POST | 54 | 59 | 60 |
| Anti-T, PRE | 54 | 59 | 60 |
| Anti-T, POST | 54 | 59 | 60 |
Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL for all antibodies assessed.
| IU/mL | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Anti-D, PRE | 0.767 (0.600 to 0.982) | 1.094 (0.874 to 1.368) | 0.686 (0.552 to 0.853) |
| Anti-D, POST | 4.251 (3.646 to 4.957) | 5.226 (4.353 to 6.275) | 4.150 (3.543 to 4.862) |
| Anti-T, PRE | 2.008 (1.650 to 2.444) | 1.987 (1.680 to 2.350) | 1.752 (1.508 to 2.037) |
| Anti-T, POST | 7.581 (6.523 to 8.809) | 8.456 (7.294 to 9.802) | 8.792 (7.582 to 10.195) |
A seropositive subject for anti-PT/anti-PRN/anti-FHA antibodies was defined as a vaccinated subject who had anti-PT/anti-PRN/anti-FHA antibody concentrations greater than or equal to (≥) 5 ELISA units per milliliter (EL.U/mL).
| Participants | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Anti-PT, PRE [N=52;58;58] | 44 | 48 | 50 |
| Anti-PT, POST [N=54;59;60] | 54 | 59 | 60 |
| Anti-PRN, PRE [N=54;59;59] | 54 | 59 | 59 |
| Anti-PRN, POST [N=53;59;60] | 53 | 59 | 60 |
| Anti-FHA, PRE [N=54;59;59] | 54 | 59 | 59 |
| Anti-FHA, POST [N=53;59;60] | 53 | 59 | 60 |
Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL.
| EL.U/mL | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Anti-PT, PRE [N=52;58;58] | 11.627 (8.863 to 15.252) | 14.193 (11.003 to 18.306) | 15.650 (11.643 to 21.035) |
| Anti-PT, POST [N=54;59;60] | 82.478 (66.951 to 101.606) | 108.094 (87.703 to 133.227) | 123.964 (103.458 to 148.533) |
| Anti-PRN, PRE [N=54;59;59] | 131.814 (98.531 to 176.340) | 161.903 (123.574 to 212.120) | 114.226 (90.201 to 144.652) |
| Anti-PRN, POST [N=53;59;60] | 445.751 (372.770 to 533.020) | 448.475 (383.748 to 524.120) | 448.839 (379.488 to 530.863) |
| Anti-FHA, PRE [N=54;59;59] | 75.574 (61.018 to 93.603) | 96.098 (75.507 to 122.305) | 97.698 (81.891 to 116.555) |
| Anti-FHA, POST [N=53;59;60] | 503.532 (426.524 to 594.444) | 592.177 (516.831 to 678.507) | 558.648 (489.266 to 637.869) |
A booster responder to PT/PRN antigens was defined as either a vaccinated subject seronegative at analysis baseline (Year 10) with anti-PT/anti-PRN antibody concentration greater than or equal to (≥) 5 EL.U/mL at one month post Year 10 booster vaccination, or as a vaccinated subject seropositive at analysis baseline (Year 10) and with anti-PT/anti-PRN antibody concentration with at least a 2-fold increase at one month post Year 10 booster vaccination. A seronegative/seropositive subject was defined as a vaccinated subject with anti-PT/anti-PRN antibody concentration ≥/\< 5 EL.U/mL.
| Participants | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Booster responses to anti-PT [N=44;51;51] | 44 | 51 | 48 |
| Booster responses to anti-PRN [N=45;52;52] | 23 | 29 | 35 |
| Booster responses to anti-FHA [N=46;52;50] | 43 | 47 | 48 |
Assessed solicited local symptoms were pain, redness and swelling at the injection site. Any = incidence of a particular symptom regardless of intensity grade.
| Participants | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Any Pain | 50 | 55 | 54 |
| Any Redness | 23 | 23 | 21 |
| Any Swelling | 21 | 20 | 19 |
Assessed solicited general symptoms were fatigue, gastrointestinal, headache and fever \[defined as axillary temperature ≥ 37.5 degrees Celsius (°C)\]. Any = incidence of a particular symptom regardless of intensity grade and relationship to vaccination.
| subjects | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Any Fatigue | 17 | 20 | 22 |
| Any Gastrointestinal Symptoms | 10 | 9 | 13 |
| Any Headache | 13 | 19 | 13 |
| Any Fever | 1 | 1 | 1 |
An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any unsolicited AE = any unsolicited AE regardless of intensity or relationship to vaccination.
| Participants | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Number of Subjects With Any Unsolicited Adverse Events (AEs). | 22 | 16 | 21 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject..
| Participants | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Number of Subjects With Any Serious Adverse Events (SAEs). | 0 | 0 | 0 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
| Participants | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| Number of Subjects With Any Serious Adverse Events (SAEs). | 0 | 0 | 0 |
Collected over Serious adverse events (SAEs): Entire study period (From Year 8.5 to one month post Year 10) ; Unsolicited adverse events (AEs): During the 31 days (Day 0 - Day 30) post Year 10 booster vaccination; Solicited symptoms: During the 4 days (Day 0 - Day 3) post Year 10 booster vaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Boostrix-US Group | — | 0/55 (0%) | 53/55 (96.4%) |
| Boostrix-INV Group | — | 0/60 (0%) | 58/60 (96.7%) |
| Boostrix-REF Group | — | 0/66 (0%) | 58/62 (93.5%) |
| Event | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group |
|---|---|---|---|
| PainGeneral disorders | 50/55 | 55/59 | 54/62 |
| RednessGeneral disorders | 23/55 | 23/59 | 21/62 |
| SwellingGeneral disorders | 21/55 | 20/59 | 19/62 |
| FatigueGeneral disorders | 17/54 | 20/59 | 22/62 |
| HeadacheGeneral disorders | 13/54 | 19/59 | 13/62 |
| Gastrointestinal symptomsGeneral disorders | 10/54 | 9/59 | 13/62 |
| NasopharyngitisInfections and infestations | 6/55 | 1/60 | 4/62 |
| HeadacheNervous system disorders | 5/55 | 1/60 | 3/62 |
At Year 8.5, a total of 180 subjects (out of the 478 planned) were enrolled: 54, 60 and 66 subjects in the Boostrix-REF, Boostrix-US, and Boostrix-INV groups, respectively. At Year 10, a total of 177 subjects (out of the 180 planned) were enrolled: 55, 60 and 62 in the Boostrix-REF, Boostrix-US, and Boostrix-INV groups, respectively.
| Age, Continuous(Years) | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group | Total |
|---|---|---|---|---|
| Mean | 22.4 ± 1.46 | 22.3 ± 1.20 | 22.3 ± 1.17 | 22.3 ± 1.18 |
| Age, Continuous(Years) | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group | Total |
|---|---|---|---|---|
| Mean | 23.5 ± 1.44 | 23.4 ± 1.21 | 23.3 ± 1.17 | 23.4 ± 1.19 |
| Sex: Female, Male(Participants) | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group | Total |
|---|---|---|---|---|
| Female | 29 | 33 | 39 | 101 |
| Male | 25 | 27 | 27 | 79 |
| Sex: Female, Male(Participants) | Boostrix-US Group | Boostrix-INV Group | Boostrix-REF Group | Total |
|---|---|---|---|---|
| Female | 29 | 31 | 36 | 96 |
| Male | 26 | 29 | 26 | 81 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jun 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Boostrix